94:I[20210,[],"IconMark"] 57:["$","meta","25",{"name":"citation_fulltext_html_url","content":"https://www.nobleid.org/work/w1/20260521/CDCD9837"}] 58:["$","meta","26",{"name":"citation_abstract_html_url","content":"https://www.nobleid.org/work/w1/20260521/CDCD9837"}] 59:["$","meta","27",{"name":"citation_keywords","content":"Acetylcysteine, Medicine, Group B, ARDS, Retrospective cohort study, Logistic regression, Internal medicine, Acute respiratory distress, Coronavirus disease 2019 (COVID-19), Gastroenterology"}] 5a:["$","meta","28",{"name":"citation_year","content":"2023"}] 5b:["$","meta","29",{"name":"DC.title","content":"Benefits of N-Acetylcysteine in the SARS-CoV-2 infection"}] 5c:["$","meta","30",{"name":"DC.creator","content":"M.A. Galindo-Andúgar"}] 5d:["$","meta","31",{"name":"DC.creator","content":"Ángel Arias"}] 5e:["$","meta","32",{"name":"DC.creator","content":"Alfonso García-Guerra"}] 5f:["$","meta","33",{"name":"DC.creator","content":"Ana Bellido-Maldonado"}] 60:["$","meta","34",{"name":"DC.creator","content":"Icíar Fernández-Visier"}] 61:["$","meta","35",{"name":"DC.creator","content":"Antonio Cantillo-Berni"}] 62:["$","meta","36",{"name":"DC.creator","content":"Sara Rodríguez Fernández"}] 63:["$","meta","37",{"name":"DC.identifier","content":"ark:/48914/w1/20260521/CDCD9837"}] 64:["$","meta","38",{"name":"DC.identifier.ark","content":"ark:/48914/w1/20260521/CDCD9837"}] 65:["$","meta","39",{"name":"DC.date","content":"2023-09-09"}] 66:["$","meta","40",{"name":"DC.language","content":"en"}] 93:T5d9,Background: N-Acetylcysteine (NAC) is a mucolytic agent but could have antioxidant and anti-inflammatory effects with higher dosage. For this reason, the use of NAC in COVID-19 has been recommended. Aim and Objectives To evaluate the impact of using N-Acetylcysteine in the evolution of the COVID-19 infection. Methods: A Retrospective single-center cohort study was conducted in our hospital. The inclusion criteria were to be admitted in our hospital during the first wave from March to April 2020 for COVID-19. The NAC was administrated orally with 600 mg twice a day. Results: A total of 378 patients were included. The gender distribution was similar (182 women, 48.1%). The average age was 73.3 ± 14.5 years and the average stay was 7 ± 4 days. Half of the patients (199, 52.6%) were treated with NAC and their characteristics were similar to the other group without statistically significant differences. The global mortality was 26.7% and it was bigger in the group without NAC (p=0.013). A multivariate analysis through logistic regression identified the treatment with N-Acetylcysteine as a protective factor (OR 0.57, CI95% 0.31 – 0.99). In regard to the Chest-X-Ray we observed more patients in the NAC group with moderate and severe acute respiratory distress syndrome (ARDS) in the admission and a bigger improvement in the discharge. Conclusions: In our study, the N-Acetylcysteine treatment in patients with COVID-19 showed a lower mortality.67:["$","meta","41",{"name":"DC.description","content":"$93"}] 68:["$","meta","42",{"name":"DC.type","content":"Journal Article"}] 69:["$","meta","43",{"name":"DC.format","content":"text/html"}] 6a:["$","meta","44",{"name":"prism.url","content":"https://www.nobleid.org/work/w1/20260521/CDCD9837"}] 6b:["$","meta","45",{"name":"prism.publicationDate","content":"2023-09-09"}] 6c:["$","meta","46",{"name":"prism.startingPage","content":"PA1693"}] 6d:["$","meta","47",{"name":"prism.endingPage","content":"PA1693"}] 6e:["$","link","48",{"rel":"canonical","href":"https://www.nobleid.org/work/w1/20260521/CDCD9837"}] 6f:["$","link","49",{"rel":"alternate","type":"application/ld+json","href":"https://www.nobleid.org/work/w1/20260521/CDCD9837.jsonld"}] 70:["$","link","50",{"rel":"alternate","type":"application/vnd.citationstyles.csl+json","href":"https://www.nobleid.org/work/w1/20260521/CDCD9837.csl.json"}] 71:["$","link","51",{"rel":"alternate","type":"application/x-bibtex","href":"https://www.nobleid.org/work/w1/20260521/CDCD9837.bib"}] 72:["$","link","52",{"rel":"alternate","type":"application/x-research-info-systems","href":"https://www.nobleid.org/work/w1/20260521/CDCD9837.ris"}] 73:["$","meta","53",{"name":"google-site-verification","content":"5p_a1UP5ZktRIEXoro_3k0IzzGqh3Xw3RJDGQ1yQxu0"}] 74:["$","meta","54",{"property":"og:title","content":"Benefits of N-Acetylcysteine in the SARS-CoV-2 infection"}] 75:["$","meta","55",{"property":"og:description","content":"Background: N-Acetylcysteine (NAC) is a mucolytic agent but could have antioxidant and anti-inflammatory effects with higher dosage. For this reason, the use of NAC in COVID-19 has been recommended. Aim and Objectives To evaluate the impact of using N-Acetylcysteine in the evolution of the COVID-19…"}] 76:["$","meta","56",{"property":"og:url","content":"https://www.nobleid.org/work/w1/20260521/CDCD9837"}] 77:["$","meta","57",{"property":"og:site_name","content":"NobleID"}] 78:["$","meta","58",{"property":"og:locale","content":"en_US"}] 79:["$","meta","59",{"property":"og:image","content":"https://www.nobleid.org/api/og/work/w1/20260521/CDCD9837"}] 7a:["$","meta","60",{"property":"og:image:width","content":"1200"}] 7b:["$","meta","61",{"property":"og:image:height","content":"630"}] 7c:["$","meta","62",{"property":"og:image:alt","content":"Benefits of N-Acetylcysteine in the SARS-CoV-2 infection"}] 7d:["$","meta","63",{"property":"og:type","content":"article"}] 7e:["$","meta","64",{"property":"article:published_time","content":"2023-09-09"}] 7f:["$","meta","65",{"property":"article:author","content":"M.A. Galindo-Andúgar"}] 80:["$","meta","66",{"property":"article:author","content":"Ángel Arias"}] 81:["$","meta","67",{"property":"article:author","content":"Alfonso García-Guerra"}] 82:["$","meta","68",{"property":"article:author","content":"Ana Bellido-Maldonado"}] 83:["$","meta","69",{"property":"article:author","content":"Icíar Fernández-Visier"}] 84:["$","meta","70",{"property":"article:author","content":"Antonio Cantillo-Berni"}] 85:["$","meta","71",{"property":"article:author","content":"Sara Rodríguez Fernández"}] 86:["$","meta","72",{"name":"twitter:card","content":"summary_large_image"}] 87:["$","meta","73",{"name":"twitter:site","content":"@NobleID"}] 88:["$","meta","74",{"name":"twitter:creator","content":"@NobleID"}] 89:["$","meta","75",{"name":"twitter:title","content":"Benefits of N-Acetylcysteine in the SARS-CoV-2 infection"}] 8a:["$","meta","76",{"name":"twitter:description","content":"Background: N-Acetylcysteine (NAC) is a mucolytic agent but could have antioxidant and anti-inflammatory effects with higher dosage. For this reason, the use of NAC in COVID-19 has been recommended. Aim and Objectives To evaluate the impact of using N-Acetylcysteine in the evolution of the COVID-19…"}] 8b:["$","meta","77",{"name":"twitter:image","content":"https://www.nobleid.org/api/og/work/w1/20260521/CDCD9837"}] 8c:["$","link","78",{"rel":"icon","href":"/favicon/favicon-16x16.png","sizes":"16x16","type":"image/png"}] 8d:["$","link","79",{"rel":"icon","href":"/favicon/favicon-32x32.png","sizes":"32x32","type":"image/png"}] 8e:["$","link","80",{"rel":"icon","href":"/favicon/favicon.ico","sizes":"any"}] 8f:["$","link","81",{"rel":"apple-touch-icon","href":"/favicon/apple-touch-icon.png","sizes":"180x180","type":"image/png"}] 90:["$","link","82",{"rel":"android-chrome-192x192","href":"/favicon/android-chrome-192x192.png","sizes":"192x192","type":"image/png"}] 91:["$","link","83",{"rel":"android-chrome-512x512","href":"/favicon/android-chrome-512x512.png","sizes":"512x512","type":"image/png"}] 92:["$","$L94","84",{}]

Benefits of N-Acetylcysteine in the SARS-CoV-2 infection

Sign in to see the full record

Benefits of N-Acetylcysteine in the SARS-CoV-2 infection

Sign in to see the full record